Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma
Published in: Blood cancer journal
Access to document
10.1038/s41408-022-00723-4
document
Diana Al-Sarayfi, Frederik O. Meeuwes, Mujde Durmaz, Djamila E. Issa, Rolf E. Brouwer, Aart Beeker, Anna van Rhenen, Pim G. N. J. Mutsaers, Lara H. Bohmer, Marjolein W. M. van der Poel, Liane te Boome, Tom van Meerten, Martine E. D. Chamuleau, Josee M. Zijlstra, Mirian Brink, Marcel Nijland
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0271807
document
INTRODUCTION: The aim of this study was to determine the efficacy of early tocilizumab treatment for hospitalized patients with COVID-19 disease. METHODS: Open-label randomized phase II clinical trial investigating tocilizumab in patients with proven COVID-19 admitted to the general ward and in need of supplemental oxygen. The primary endpoint of the study was 30-day mortality with a prespecified 2-sided significance level of α = 0.10. A post-hoc analysis was performed for a combined endpoint of mechanical ventilation or death at 30 days. Secondary objectives included comparing the duration...
Abraham Rutgers, Peter E Westerweel, Bronno van der Holt, Simone Postma, Marit G A van Vonderen, Djura P Piersma, Douwe Postma, Maarten van den Berge, Eefje Jong, Marten de Vries, Leonie van der Burg, Dennis Huugen, Marjolein van der Poel, Linda M Kampschreur, Marcel Nijland, Jaap H Strijbos, Menno Tamminga, Pim G N J Mutsaers, Suzanne Schol-Gelok, Margriet Dijkstra-TiekstraGrigory Sidorenkov, Julien Vincenten, Wouter H van Geffen, Marjolein Knoester, Jos Kosterink, Reinold Gans, Coen Stegeman, Gerwin Huls, Tom van Meerten
CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies
Published in: Clinical and Translational Medicine
Access to document
10.1002/ctm2.943
document
BACKGROUND: The CD47-signal regulatory protein alpha (SIRPα) ‘don’t eat me’ signalling axis is perhaps the most prominent innate immune checkpoint to date. However, from initial clinical trials, it is evident that monotherapy with CD47-SIRPα blocking has a limited therapeutic effect at the maximum tolerated dose. Furthermore, treatment is associated with severe side effects, most notably anaemia, that are attributable to the ubiquitous expression of CD47. Nevertheless, promising clinical responses have been reported upon combination with the tumour-targeting antibody rituximab or azacytidine, although toxicity issues still hamper clinical application....
Renée Bouwstra, Tom van Meerten, Edwin Bremer
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
Published in: -
Access to document
10.1182/bloodadvances.2021006922
document
Gloria Iacoboni, Kai Rejeski, Guillermo Villacampa, Jaap A. van Doesum, Annalisa Chiappella, Francesca Bonifazi, Lucia Lopez-Corral, Michiel van Aalderen, Mi Kwon, Nuria Martinez-Cibrian, Stefania Bramanti, Juan Luis Reguera-Ortega, Lina Camacho-Arteaga, Christian Schmidt, Ana Marin-Niebla, Marie Jose Kersten, Alejandro Martin Garcia-Sancho, Pier Luigi Zinzani, Paolo Corradini, Tom van MeertenMarion Subklewe, Pere Barba
CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
Published in: Biomedicines
Access to document
10.3390/biomedicines10051175
document
CD24 and its ligand Siglec-10 were described as an innate immune checkpoint in carcinoma. Here, we investigated this axis in B-cell lymphoma by assessing CD24 expression and evaluating pro-phagocytic effects of CD24 antibody treatment in comparison to hallmark immune checkpoint CD47. In mantle cell lymphoma (MCL) and follicular lymphoma patients, high mRNA expression of CD24 correlated with poor overall survival, whereas CD47 expression did not. Conversely, CD24 expression did not correlate with survival in diffuse large B-cell lymphoma (DLBCL), whereas CD47 did. CD24 was also highly expressed on...
Jimena Álvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena González Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, Edwin Bremer